{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:55:58Z","timestamp":1778716558243,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010870","name":"Qingdao Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Grant No. 21-1-4-rkjk-7-nsh"],"award-info":[{"award-number":["Grant No. 21-1-4-rkjk-7-nsh"]}],"id":[{"id":"10.13039\/501100010870","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["Grant No.ZR2023MH231"],"award-info":[{"award-number":["Grant No.ZR2023MH231"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15010-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:38:23Z","timestamp":1763714303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence"],"prefix":"10.1186","volume":"25","author":[{"given":"Yihao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengwen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianzhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"8","key":"15010_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/13543784.2021.1948999","volume":"30","author":"RI Bin","year":"2021","unstructured":"Bin RI, Khan AM, Catto JW, Hussain SA. Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. Expert Opin Inv Drug. 2021;30(8):837\u201355.","journal-title":"Expert Opin Inv Drug"},{"issue":"3","key":"15010_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358.","journal-title":"Ann Oncol"},{"issue":"2","key":"15010_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21(2):104\u201321.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"15010_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"M Cumberbatch","year":"2018","unstructured":"Cumberbatch M, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784\u201395.","journal-title":"Eur Urol"},{"issue":"1","key":"15010_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2020.1702025","volume":"13","author":"K Montazeri","year":"2020","unstructured":"Montazeri K, Bellmunt J. Erdafitinib for the treatment of metastatic bladder cancer. Expert Rev Clin Pharmacol. 2020;13(1):1\u20136.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"15010_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s12094-024-03697-w","volume":"27","author":"Z Li","year":"2025","unstructured":"Li Z, Li J, Bai X, Huang X, Wang Q. Tumor microenvironment as a complex milieu driving cancer progression: a mini review. Clin Transl Oncol. 2025;27(5):1943\u201352.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"15010_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mc.23475","volume":"62","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zheng Z, Mao S, Yang F, Wang R, Wang H, et al. Metabolic-associated signature and hub genes associated with immune microenvironment and prognosis in bladder cancer. Mol Carcinog. 2023;62(2):185\u201399.","journal-title":"Mol Carcinog"},{"issue":"10","key":"15010_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","volume":"24","author":"S Guelfi","year":"2024","unstructured":"Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer. 2024;24(10):655\u201375.","journal-title":"Nat Rev Cancer"},{"key":"15010_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0076-6879(04)81023-1","volume":"381","author":"P Vaupel","year":"2004","unstructured":"Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Method Enzymol. 2004;381:335\u201354.","journal-title":"Method Enzymol"},{"issue":"1","key":"15010_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02148-4","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Liu F, Cai Q, Deng L, Ouyang Q, Zhang XH, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Signal Transduct Target Ther. 2025;10(1):57.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"15010_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11033-023-08931-2","volume":"51","author":"S Lin","year":"2023","unstructured":"Lin S, Chai Y, Zheng X, Xu X. The role of Hif in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers. Mol Biol Rep. 2023;51(1):14.","journal-title":"Mol Biol Rep"},{"key":"15010_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.115672","volume":"229","author":"P He","year":"2023","unstructured":"He P, Dai Q, Wu X. New insight in urological cancer therapy: from epithelial-mesenchymal transition (EMT) to application of nano-biomaterials. Environ Res. 2023;229:115672.","journal-title":"Environ Res"},{"issue":"9","key":"15010_CR13","first-page":"2196","volume":"18","author":"I Kawahara","year":"2024","unstructured":"Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, et al. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol. 2024;18(9):2196\u2013211.","journal-title":"Mol Oncol"},{"issue":"1","key":"15010_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00018.2019","volume":"100","author":"C Riera-Domingo","year":"2020","unstructured":"Riera-Domingo C, Audige A, Granja S, Cheng WC, Ho PC, Baltazar F, et al. Immunity, hypoxia, and metabolism-the menage a trois of cancer: implications for immunotherapy. Physiol Rev. 2020;100(1):1\u2013102.","journal-title":"Physiol Rev"},{"issue":"1","key":"15010_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"1","key":"15010_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10020-025-01205-6","volume":"31","author":"W Zhang","year":"2025","unstructured":"Zhang W, Xia M, Li J, Liu G, Sun Y, Chen X, et al. Warburg effect and lactylation in cancer: mechanisms for chemoresistance. Mol Med. 2025;31(1):146.","journal-title":"Mol Med"},{"issue":"7","key":"15010_CR17","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1158\/0008-5472.CAN-10-2828","volume":"71","author":"F Vegran","year":"2011","unstructured":"Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB\/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 2011;71(7):2550\u201360.","journal-title":"Cancer Res"},{"issue":"1","key":"15010_CR18","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-022-32521-8","volume":"13","author":"Q Feng","year":"2022","unstructured":"Feng Q, Liu Z, Yu X, Huang T, Chen J, Wang J, et al. Lactate increases stemness of CD8\u2009+\u2009T cells to augment anti-tumor immunity. Nat Commun. 2022;13(1):4981.","journal-title":"Nat Commun"},{"issue":"13","key":"15010_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136995","volume":"22","author":"AJ Boutilier","year":"2021","unstructured":"Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22(13):6995.","journal-title":"Int J Mol Sci"},{"key":"15010_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101248","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, Wang H, Cui Z, Yu T, Song Y, Gao H, et al. Lactylation in cancer progression and drug resistance. Drug Resist Updat. 2025;81:101248.","journal-title":"Drug Resist Updat"},{"key":"15010_CR21","doi-asserted-by":"publisher","first-page":"1467052","DOI":"10.3389\/fimmu.2024.1467052","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang X, Liu Y, Xu J, Zhu J, Zheng Y, et al. A novel hypoxia- and lactate metabolism-related prognostic signature to characterize the immune landscape and predict immunotherapy response in osteosarcoma. Front Immunol. 2024;15:1467052.","journal-title":"Front Immunol"},{"key":"15010_CR22","doi-asserted-by":"publisher","first-page":"998140","DOI":"10.3389\/fimmu.2022.998140","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Qiao H, Wu F, Sun S, Feng C, Li C, et al. A novel hypoxia- and lactate metabolism-related signature to predict prognosis and immunotherapy responses for breast cancer by integrating machine learning and bioinformatic analyses. Front Immunol. 2022;13:998140.","journal-title":"Front Immunol"},{"issue":"4","key":"15010_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420\u201333.","journal-title":"Eur Urol"},{"key":"15010_CR24","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. Oncopredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","DOI":"10.1093\/bib\/bbab260"},{"issue":"11","key":"15010_CR25","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1681\/ASN.2019040335","volume":"30","author":"Z Yu","year":"2019","unstructured":"Yu Z, Liao J, Chen Y, Zou C, Zhang H, Cheng J, et al. Single-cell transcriptomic map of the human and mouse bladders. J Am Soc Nephrol. 2019;30(11):2159\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"15010_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12935-021-01954-4","volume":"21","author":"X Sun","year":"2021","unstructured":"Sun X, Zhou Z, Zhang Y, Wang J, Zhao X, Jin L, et al. Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer. Cancer Cell Int. 2021;21(1):251.","journal-title":"Cancer Cell Int"},{"key":"15010_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3170950","volume":"2022","author":"X Sun","year":"2022","unstructured":"Sun X, Zhang Y, Chen Y, Xin S, Jin L, Liu X, et al. In silico establishment and validation of novel lipid metabolism-related gene signature in bladder cancer. Oxid Med Cell Longev. 2022;2022:3170950.","journal-title":"Oxid Med Cell Longev"},{"key":"15010_CR28","doi-asserted-by":"crossref","unstructured":"Shi W, Dong J, Zhong B, Hu X, Zhao C. Predicting the prognosis of bladder cancer patients through integrated multi-omics exploration of chemotherapy-related hypoxia genes. Mol Biotechnol. 2025;67(6):2367\u201381.","DOI":"10.1007\/s12033-024-01203-9"},{"issue":"1","key":"15010_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01631-8","volume":"15","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Chai Y, Li Y, Zhang Y, Wang T. Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by Nmf clustering and building related signature. Discover Oncol. 2024;15(1):796.","journal-title":"Discover Oncol"},{"issue":"20","key":"15010_CR30","doi-asserted-by":"publisher","first-page":"e1982112175","DOI":"10.1073\/pnas.2312855121","volume":"121","author":"W Jing","year":"2024","unstructured":"Jing W, Wang G, Cui Z, Li X, Zeng S, Jiang X, et al. Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proc Natl Acad Sci U S A. 2024;121(20):e1982112175.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"15010_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2024.01.023","volume":"86","author":"NF Debatin","year":"2024","unstructured":"Debatin NF, Bady E, Mandelkow T, Huang Z, Lurati M, Raedler JB, et al. Prognostic impact and spatial interplay of immune cells in urothelial cancer. Eur Urol. 2024;86(1):42\u201351.","journal-title":"Eur Urol"},{"issue":"3","key":"15010_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/PAP.0000000000000152","volume":"24","author":"GP Paner","year":"2017","unstructured":"Paner GP, Montironi R, Amin MB. Challenges in pathologic staging of bladder cancer: proposals for fresh approaches of assessing pathologic stage in light of recent studies and observations pertaining to bladder histoanatomic variances. Adv Anat Pathol. 2017;24(3):113\u201327.","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"15010_CR33","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1097\/JS9.0000000000001194","volume":"110","author":"Z Wei","year":"2024","unstructured":"Wei Z, Xv Y, Liu H, Li Y, Yin S, Xie Y, et al. A ct-based deep learning model predicts overall survival in patients with muscle invasive bladder cancer after radical cystectomy: a multicenter retrospective cohort study. Int J Surg. 2024;110(5):2922\u201332.","journal-title":"Int J Surg"},{"issue":"19","key":"15010_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70111","volume":"28","author":"S Li","year":"2024","unstructured":"Li S, Zheng F, Wang Z, Xiong S, Zeng J, Xu S, et al. Integrated analysis of bulk and single-cell RNA-seq data reveals cell differentiation-related subtypes and a scoring system in bladder cancer. J Cell Mol Med. 2024;28(19):e70111.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"15010_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MOU.0000000000001183","volume":"34","author":"R Grausenburger","year":"2024","unstructured":"Grausenburger R, Herek P, Shariat SF, Englinger B. Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer. Curr Opin Urol. 2024;34(4):236\u201343.","journal-title":"Curr Opin Urol"},{"issue":"1","key":"15010_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03132-4","volume":"24","author":"J Sun","year":"2024","unstructured":"Sun J, Jiang R, Hou L, Wang L, Li M, Dong H, et al. Identification of a combined hypoxia and lactate metabolism prognostic signature in lung adenocarcinoma. BMC Pulm Med. 2024;24(1):323.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"15010_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12967-024-05391-5","volume":"22","author":"A Huang","year":"2024","unstructured":"Huang A, Sun Z, Hong H, Yang Y, Chen J, Gao Z, et al. Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer. J Transl Med. 2024;22(1):587.","journal-title":"J Transl Med"},{"issue":"1","key":"15010_CR38","first-page":"820","volume":"16","author":"Y Deng","year":"2024","unstructured":"Deng Y, Zhu G, Mi X, Jing X. Prognostic implication of a novel lactate score correlating with immunotherapeutic responses in pan-cancer. Aging (Albany Ny). 2024;16(1):820\u201343.","journal-title":"Aging (Albany Ny)"},{"issue":"13","key":"15010_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. New Engl J Med. 2020;383(13):1218\u201330.","journal-title":"New Engl J Med"},{"issue":"3","key":"15010_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (checkmate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15010_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0667-0","volume":"7","author":"A Osipov","year":"2019","unstructured":"Osipov A, Saung MT, Zheng L, Murphy AG. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019;7(1):224.","journal-title":"J Immunother Cancer"},{"key":"15010_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217417","volume":"611","author":"H Liu","year":"2024","unstructured":"Liu H, Zhao H, Zhou M, Zhao X, Lu Y. Neutrophils in cancer drug resistance: roles and therapeutic opportunities. Cancer Lett. 2024;611:217417.","journal-title":"Cancer Lett"},{"issue":"4","key":"15010_CR43","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","volume":"174","author":"AG Robertson","year":"2018","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018;174(4):1033.","journal-title":"Cell"},{"issue":"9","key":"15010_CR44","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","volume":"70","author":"D Lindgren","year":"2010","unstructured":"Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70(9):3463\u201372.","journal-title":"Cancer Res"},{"issue":"1","key":"15010_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22465-w","volume":"12","author":"SV Lindskrog","year":"2021","unstructured":"Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtroder K, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021;12(1):2301.","journal-title":"Nat Commun"},{"issue":"7492","key":"15010_CR46","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Comprehensive molecular characterization of urothelial bladder carcinoma","year":"2014","unstructured":"Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315\u201322.","journal-title":"Nature"},{"issue":"18","key":"15010_CR47","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the getug-afu v05 vesper trial. J Clin Oncol. 2022;40(18):2013\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15010_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202451215","volume":"55","author":"R Tang","year":"2025","unstructured":"Tang R, Tay SS, Sharbeen G, Herrmann D, Youkhana J, Timpson P, et al. Bystander expression of atypical chemokine receptor 2 protects t cells from chemoattraction towards cancer-associated fibroblasts. Eur J Immunol. 2025;55(2):e202451215.","journal-title":"Eur J Immunol"},{"issue":"9","key":"15010_CR49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41419-023-06114-2","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Zhou Y, Ning L, Chen J, Chen H, Li X. Knockdown of anxa10 induces ferroptosis by inhibiting autophagy-mediated Tfrc degradation in colorectal cancer. Cell Death Dis. 2023;14(9):588.","journal-title":"Cell Death Dis"},{"issue":"24","key":"15010_CR50","doi-asserted-by":"publisher","first-page":"22395","DOI":"10.1002\/cam4.6759","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Sun L, Zheng B, Wang H, Qin X, Zhang P, et al. The value of ATAD3A as a potential biomarker for bladder cancer. Cancer Med. 2023;12(24):22395\u2013406.","journal-title":"Cancer Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:03:43Z","timestamp":1763723023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15010"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15010-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Qilu Hospital of Shandong University (Approval No.: KYLL-202407(X)-Z046-1). Our study obtained informed consent from all participants and was in compliance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1796"}}